The Full Wiki

More info on CX-691

CX-691: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

(Redirected to Farampator article)

From Wikipedia, the free encyclopedia

Farampator
Systematic (IUPAC) name
2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone
Identifiers
CAS number 211735-76-1
ATC code none
PubChem 4118151
Chemical data
Formula C12H13N3O2 
Mol. mass 231.25052 g/mol
SMILES eMolecules & PubChem
Synonyms Farampator, CX-691
Therapeutic considerations
Pregnancy cat.  ?
Legal status Investigational New Medicine

Farampator (CX-691, ORG-24448) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator has been transferred, and development is continuing.

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's Disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects (SEs) such as headache, somnolence and nausea. Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs. Additional analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs. [1]

References

  1. ^ Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. PMID 17119538
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message